Taranabant cuts the fat: new hope for cannabinoid-based obesity therapies?
- PMID: 18177717
- DOI: 10.1016/j.cmet.2007.12.006
Taranabant cuts the fat: new hope for cannabinoid-based obesity therapies?
Abstract
Endocannabinoid/cannabinoid receptor signaling acts centrally and peripherally to govern appetite and energy balance. While system stimulation promotes eating and energy storage, receptor blockade can reduce food intake and facilitate weight loss. In this issue of Cell Metabolism, Addy et al. (2008) test the therapeutic antiobesity potential of taranabant, a cannabinoid 1 receptor inverse agonist.
Comment on
-
The acyclic CB1R inverse agonist taranabant mediates weight loss by increasing energy expenditure and decreasing caloric intake.Cell Metab. 2008 Jan;7(1):68-78. doi: 10.1016/j.cmet.2007.11.012. Cell Metab. 2008. PMID: 18177726 Clinical Trial.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Medical
